Sara Nayeem, M.D. is Executive Vice President, Investments at Enavate Sciences. She focuses on portfolio strategy and plays a key role in the origination, evaluation, and selection of Enavates’ partner companies. Additionally, she supports our portfolio with capital formation, strategic and select operational decisions. Sara currently serves as a board observer for BridgeBio Oncology Therapeutics.

Sara has 20 years of experience in biotech investing and advisory services. She most recently served as Partner at Avoro Ventures, a biopharma venture fund she helped launch in 2021. Previously she was a Partner at New Enterprise Associates, Inc. (NEA), where she spent 12 years as part of the biopharma investing group. Over her investing career, Sara has played a key diligence and management role in 28 investments, from which there have been 11 IPOs and 10 acquisitions with upfront payments exceeding $16 billion. Prior to joining NEA, Sara was an investment associate at Merrill Lynch, and she started her career as an investment banking analyst at Morgan Stanley banking. Sara has conducted basic science research in mammalian cardiac development and clinical research in age-related macular degeneration. She serves on the board of No Patient Left Behind, on the Advisory Board for The Blavatnik Fund for Innovation at Yale, and on the Memorial Sloan Kettering Technology Development Fund Review Committee.

Sara earned her A.B. in Biology from Harvard College and concurrent M.D./MBA degrees from Yale University.

Return to Team